AMENDMENT
NO. 1 DATED NOVEMBER 20, 2026
To
Prospectus Supplement dated February 27, 2025
(To
Prospectus Dated January 24, 2024) |
Filed
pursuant to Rule 424(b)(5)
Registration
No. 333-276676 |

IVEDA
SOLUTIONS, INC.
Up
to $1,368,350
Common
Stock
This
Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends and supplements the information in our prospectus, dated
January 24, 2024 (the “Prospectus”), and the prospectus supplement, dated February 27, 2025 (the “Prospectus Supplement”),
which was filed pursuant to our registration statement on Form S-3 (File No. 333-276676) (the “Registration Statement”).
This Amendment should be read in conjunction with the Prospectus and Prospectus Supplement, and is qualified by reference thereto, except
to the extent that the information herein amends or supersedes the information contained in the Prospectus and the Prospectus Supplement.
This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus and Prospectus Supplement,
and any future amendments or supplements thereto.
This
Amendment is being filed in connection with our previously announced “at the market offering” program, and to update the
maximum amount of shares of our common stock, par value $0.00001 per share, that we may issue and sell from time to time through or to
H.C. Wainwright & Co., LLC (the “Agent”) as sales agent or principal, pursuant to the terms of our previously announced
At the Market Offering Agreement, dated February 27, 2025, between us and the Agent (the “Sales Agreement”).
Our
common stock is listed on The Nasdaq Capital Market under the symbol “IVDA”. As of November 18, 2026, the aggregate market
value of our common stock held by non-affiliates, or the public float, pursuant to General Instruction I.B.6 of Form S-3 was approximately
$4,105,052, which was calculated based on 13,242,102 shares of our common stock outstanding held by non-affiliates as of November 18,
2026 at a price of $0.31 per share, the closing sale price for our common stock on September 23, 2026. As of the date hereof, we have
not offered and sold any shares of our common stock pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month
period that ends on and includes the date hereof. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities
in public primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6)
in any 12-calendar month period so long as our public float remains below $75 million.
We
are filing this Amendment to amend the Prospectus Supplement to update the maximum amount we are eligible to sell under our Registration
Statement pursuant to General Instruction I.B.6 of Form S-3. Accordingly, in accordance with the terms of the Sales Agreement, we may
currently offer and sell additional shares of common stock through or to the Agent having an aggregate offering price of up to $1,368,350
pursuant to the Prospectus and Prospectus Supplement, as amended by this Amendment. In the event that our public float increases such
that we may sell additional amounts under the Sales Agreement, Prospectus and Prospectus Supplement, we will file another amendment to
the Prospectus Supplement prior to making additional sales.
Investing
in our common stock involves risks. You should carefully consider the risks described under “Risk Factors” in the Prospectus
and Prospectus Supplement, as well as those described in our other reports and documents we filed with the Securities and Exchange Commission
(the “SEC”) that we incorporate by reference in the Prospectus, the Prospectus Supplement and this Amendment, before making
a decision to invest in our common stock.
Neither
the SEC, any state securities commission, nor any other regulatory body has approved or disapproved of these securities or determined
if this Amendment is accurate or complete. Any representation to the contrary is a criminal offense.
H.C.
Wainwright & Co.
The
date of this Amendment No. 1 to Prospectus Supplement is November 20, 2026.